| Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects? | |
| | |
MedLine Citation:
|
PMID: 20303610 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Inhibitors of dipeptidyl peptidase-IV (DPP-IV) are a novel class of anti-diabetes drugs; inhibiting the breakdown of incretins, they increase their biological availability and decrease thus blood glucose levels. However, in addition to regulating glucose homeostasis, DPP-IV has many diverse functions, such as modulating cell growth, differentiation and transformation and immune function. Within the immune system, DPP-IV exerts mainly stimulating effects, while its relation to malignancies is highly variable. Therefore, long-term inhibition of this enzyme could have serious side effects including immune dysregulation or increased risk of cancer. Although the data on the effects of DPP-IV inhibitors in humans are scarce, the increased risk of infections and the tendency towards a higher incidence of some tumours fall in line with experimental evidence suggesting the possibility of their adverse immunological and oncological effects. Further research is obviously needed to clarify the effector mechanisms of DPP-IV inhibitors on immune function and tumour biology. Most important, however, is obtaining reassuring safety data from adequately powered, long-term trials of DPP-IV inhibitors in humans. In the meantime, all the potential risks of DPP-IV inhibitors should be kept in mind, and this class of drugs needs to be regarded with some degree of caution. |
| | |
Authors:
|
Tomas Stulc; Aleksi Sedo |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review Date: 2010-03-19 |
Journal Detail:
|
Title: Diabetes research and clinical practice Volume: 88 ISSN: 1872-8227 ISO Abbreviation: Diabetes Res. Clin. Pract. Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-04-26 Completed Date: 2010-08-13 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8508335 Medline TA: Diabetes Res Clin Pract Country: Ireland |
Other Details:
|
Languages: eng Pagination: 125-31 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 Elsevier Ireland Ltd. All rights reserved. |
Affiliation:
|
3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic. tstulc@lf1.cuni.cz |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Dipeptidyl-Peptidase IV Inhibitors
/
adverse effects*,
therapeutic use Humans Hypoglycemic Agents Immune System / drug effects* Incretins Neoplasms / chemically induced* |
| Chemical | |
Reg. No./Substance:
|
0/Dipeptidyl-Peptidase IV Inhibitors; 0/Hypoglycemic Agents; 0/Incretins |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Carotenoid production in Lactobacillus plantarum.
Next Document: Extracellular production of reactive oxygen species during seed germination and early seedling growt...